Science Videos

from AP, Reuters, AFP, and other news services

Ebola: Who gets access to experimental drug

Date:
August 11, 2014
Source:
AP / Powered by NewsLook.com
Summary:
The use of an experimental drug to treat two Americans and a Spaniard diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies. AP medical writer Lauran Neergaard takes a closer look. (Aug. 11) Video provided by AP


Related Videos

last updated on 2014-09-16 at 3:56 pm EDT

Federal Government Needs More Marijuana for Research Studies

Federal Government Needs More Marijuana for Research Studies

TheStreet (May 9, 2014) — The National Institute for Drug Abuse, or NIDA, has asked the Drug Enforcement Agency for more marijuana. NIDA has requested an increase from 21,000 grams to 650,000 grams, or roughly 1,433 pounds of pot. As of January, NIDA has funded 28 active grants related to therapeutic uses of marijuana in six different disease categories covering AIDS, pain, schizophrenia, seizures and hard drug withdrawal. But NIDA frequently contradicts on the subject of marijuana: a NIDA-funded study at Yale looking at cannabis as a treatment for schizophrenia warned that marijuana could worsen the condition. NIDA gets its pot from The University of Mississippi, the only legal marijuana farm that grows pot for the government. The request is now open to the public for comment. Video provided by TheStreet
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
UN: Ebola Cases Could Eventually Reach 20,000

UN: Ebola Cases Could Eventually Reach 20,000

AP (Aug. 28, 2014) — The Ebola outbreak in West Africa eventually could exceed 20,000 cases, more than six times as many as are known now, the World Health Organization said as the US announced plans to test an experimental Ebola vaccine. (Aug. 28) Video provided by AP
Powered by NewsLook.com
Amid Grave Ebola Estimates, US to Test Vaccine

Amid Grave Ebola Estimates, US to Test Vaccine

AP (Aug. 28, 2014) — The National Institutes of Health will start the first human safety trials of an experimental Ebola vaccine next week, amid a grave estimate from the World Health Organization that Ebola cases in West Africa could top 20,000. (Aug. 28) Video provided by AP
Powered by NewsLook.com

Related Stories


Share This



Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins